DDInter548 DDInter1581
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Repaglinide
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Repaglinide
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Dienestrol
Dienestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Diethylstilbestrol {u} (Compound) binds {v} (Gene) TTR
TTR {u} (Gene) interacts with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Repaglinide
Diethylstilbestrol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Repaglinide (Compound)
Diethylstilbestrol (Compound) resembles Dienestrol (Compound) and Dienestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Diethylstilbestrol (Compound) binds TTR (Gene) and TTR (Gene) interacts with ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)